Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation: a systematic review and meta-analysis of phase III randomized clinical trials

CONCLUSION: Rucaparib demonstrated significant efficacy in improving PFS and ORR in ovarian cancer patients, particularly those having BRCA mutations. However, they should be closely monitored due to the greater risk of various adverse effects.PMID:38252024 | DOI:10.1080/14737140.2024.2309177

Source: Expert Review of Anticancer Therapy - January 22, 2024 Category: Cancer & Oncology Authors: Mus'ab Theeb Mustafa Aws Khalid Abushanab Mahmoud Taysir Mousa Rana Ahmed Qawaqzeh Hamza Muneer Alakhras Ahmad Sami Othman Ahmad Sa'ed Source Type: research